This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 2 EPO patents. Top assignee: Edimer Pharmaceuticals, Inc.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Innovator Spotlight: Christine Kowalczyk and Her Patent in Genetic Disorders
Introduction: Christine Kowalczyk is a prominent inventor based in Lausanne, Switzerland. With a keen focus on addressing genetic disorders, she has made significant strides in her research and has been awarded a patent for her groundbreaking work in the treatment of X-linked hypohidrotic ectodermal dysplasia (XLHED).
Latest Patents: Kowalczyk's patent, titled "Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist," relates to innovative methods for the temporal administration of EDA (ectodysplasin A) agonists. The invention emphasizes the importance of correlating therapeutic responses to optimal windows for the administration of EDA-dependent structures, particularly ectodermal appendages. This patent includes the use of EDI200, which proposes targeted therapeutic dosing and administration regimens to correct or alter abnormal phenotypes associated with XLHED.
Career Highlights: At Edimer Pharmaceuticals, Inc., Kowalczyk works at the forefront of research and development. Her contributions to the field of genetics, particularly in therapies for rare disorders, have established her as an influential figure in biotechnology. Her dedication to improving patient outcomes exemplifies her commitment to harnessing innovation for therapeutic advancements.
Collaborations: Throughout her career, Kowalczyk has collaborated with experts in the field, including her colleague, Pascal Schneider. Together, they have worked on advancing treatments that target specific genetic profiles, thereby enhancing the potential for success in therapeutic interventions.
Conclusion: Christine Kowalczyk's innovative approach to treating genetic disorders through her patent on XLHED showcases the impactful work being done in the field of biotechnology. Her collaborations and commitment to targeted therapies illustrate the essential role inventors play in transforming medical treatments for genetic conditions. With ongoing research and development, Kowalczyk's contributions are sure to leave a lasting impact on the future of genetic therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile